G-CSF动员的HLA-Mismatched-BPSC输注联合化疗治疗恶性血液病安全性观察

To observe the safety of G-CSF mobilizated HLA-mismatched peripheral blood stem cells infusion plus chemotherapy in the treatment of malignant ematological diseases

目的观察G-CSF(粒细胞集落刺激因子)动员的HLA-Mismatched-BPSC(活化HLA错配的外周血造血干细胞)输注联合化疗治疗恶性血液病的安全性。方法 10例恶性血液病患者G-CSF动员的HLA-Mismatched-BPSC输注联合化疗,观察其嵌合度、不良反应及血细胞恢复时间。结果 10例恶性血液病患者于化疗24~48 h后输注G-CSF动员的HLA-MismatchedBPSC,仅1例患者出现短暂嵌合,其余9例未检测出嵌合,干细胞输注后24 h内10例患者均出现发热,经对症处理后均能缓解,4例患者出现一过性皮疹经抗过敏治疗2 d内消退;无肝、肾功能损害、出血及腹泻等GVHD表现。4例自身对照患者血细胞恢复时间较仅接受化疗有缩短倾向。结论 G-CSF动员的HLA-Mismatched-BPSC输注联合化疗,仅1例有短暂嵌合,无GVHD发生及严重不良反应。

Objective To observe the safety of G-CSF mobilizated HLA-mismatched peripheral blood stem cells infusion plus chemotherapy in the treatment of malignant hematological diseases. Methods Ten cases of patients with hematologic malignancies were treated with HLA-mismatched peripheral blood stem cells infusion combined with chemotherapy. To observe the chimerism,adverse reactions,and the time of hematopoietic recovery of the patients. Results 10 cases of patients with hematologic malignancies were treated with HLA-mismatched peripheral blood stem cells combined infusion in 24 ~ 48 hours after chemotherapy. Only 1 patient was detected the transient chimerism and the remaining 9 patients were failed to detect the chimerism. The fever was appeared in 24 hours after infusion of stem cells and can be alleviated after symptomatic treatment in all patients,in 4 patients skin rash were appeared and can be alleviated in 2 days after anti allergy treatment. all patients had no kidney dysfunction,liver dysfunction,bleeding,diarrhea and other GVHD features. The time of hematopoietic recovery has the shortened tendency in 4 compared pateints who were treated with HLA-mismatched peripheral blood stem cells infusion combined chemotherapy and with only chemotherapy treatment. Conclusion Only 1 patient was detected the transient chimerism in 10 cases of patients who were treated with HLA-mismatched peripheral blood stem cells combined infusion with chemotherapy. All patients had no GVHD features and other serious adverse reactions.